BTI
TCRT icon

Blue Trust Inc’s Alaunos Therapeutics TCRT Stock Holding History

Blue Trust Inc’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$305 Hold
135
– – ﹤0.01% 2378
2026
Q1 		$386 Hold
135
– – ﹤0.01% 2368
2025
Q4 		$436 Hold
135
– – ﹤0.01% 2415
2025
Q3 		$325 Buy
+135
New +$385 ﹤0.01% 2475

Other funds holding TCRT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Blue Trust Inc's TCRT Position: Q2 2026 in Review

Blue Trust Inc held its Alaunos Therapeutics (TCRT) position steady in Q2 2026 at 135 shares worth $305. The position accounts for ﹤0.01% of the portfolio, ranked #2378.

Blue Trust Inc first reported a position in TCRT in Q3 2025 and has held it in 4 quarters since. The position peaked at $436 in Q4 2025. 29 funds tracked by Wall St. Rank hold TCRT as of Q2 2026.

  • Blue Trust Inc held 135 shares of Alaunos Therapeutics worth $305 as of Q2 2026.
  • Blue Trust Inc left its Alaunos Therapeutics share count unchanged in Q2 2026.
  • Alaunos Therapeutics made up ﹤0.01% of Blue Trust Inc's portfolio in Q2 2026, its #2378 holding.
  • Blue Trust Inc first reported a position in Alaunos Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Blue Trust Inc's Alaunos Therapeutics position peaked at $436 in Q4 2025.
  • 29 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2026.

Based on Blue Trust Inc's 13F filing for Q2 2026, filed 21 Jul 2026.